Cargando…

Mesenchymal-Epithelial Transition Exon 14 Skipping Mutation and Amplification in 5,008 Patients With Lung Cancer

BACKGROUND: Lung cancer is a major health concern worldwide because of its increasing incidence and mortality. This study aimed to clarify the association between mesenchymal-epithelial transition (MET) genomic alterations and clinical characteristics of lung cancer. METHOD: We collected data from 5...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Yaolin, Li, Guangqi, Ju, Kun, Ran, Wenwen, Zhao, Han, Liu, Xianglan, Hou, Mingyu, He, Yulu, Chen, Yang, Zang, Guoliang, Xing, Xiaoming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515048/ https://www.ncbi.nlm.nih.gov/pubmed/34660325 http://dx.doi.org/10.3389/fonc.2021.755031

Ejemplares similares

MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
por: Lung, Jrhau, et al.
Publicado: (2019)

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study
por: Liu, Xue-wen, et al.
Publicado: (2020)

ExonSkipDB: functional annotation of exon skipping event in human
por: Kim, Pora, et al.
Publicado: (2020)

Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
por: Sohn, Sung-Hwa, et al.
Publicado: (2022)

Exon skipping for DMD
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2012)

Epigenetic modulator UVI5008 inhibits MRSA by interfering with bacterial gyrase
por: Franci, Gianluigi, et al.
Publicado: (2018)

Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
por: Katakura, Seigo, et al.
Publicado: (2019)

Combinatorial Pattern of Histone Modifications in Exon Skipping Event
por: Chen, Wei, et al.
Publicado: (2019)

Natural Exon Skipping Sets the Stage for Exon Skipping as Therapy for Dystrophic Epidermolysis Bullosa
por: Bremer, Jeroen, et al.
Publicado: (2019)

Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer
por: Watari, Naokazu, et al.
Publicado: (2022)

Genomic and transcriptomic insights into the thermo-regulated biosynthesis of validamycin in Streptomyces hygroscopicus 5008
por: Wu, Hang, et al.
Publicado: (2012)

Therapeutic exon skipping for dysferlinopathies?
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2010)

The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification
por: Choi, Wonyoung, et al.
Publicado: (2021)

Fmr1 exon 14 skipping in late embryonic development of the rat forebrain
por: Corrêa-Velloso, Juliana C., et al.
Publicado: (2022)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
por: Ding, Caixia, et al.
Publicado: (2023)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Targeted Exon Skipping to Correct Exon Duplications in the Dystrophin Gene
por: Greer, Kane L, et al.
Publicado: (2014)

Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report
por: Qin, Ruo-Yan, et al.
Publicado: (2021)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping
por: Chen, Hualin, et al.
Publicado: (2022)

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
por: Błaszkowska, M., et al.
Publicado: (2022)

Non-small cell lung cancer with MET exon 14 skip mutation: case report
por: Clough, Wolfgang, et al.
Publicado: (2022)

MET exon 14 skipping is overexpressed in an allele-specific manner in lung adenocarcinoma primary samples
por: Durham, Megan, et al.
Publicado: (2023)

Insecticide resistance mediated by an exon skipping event
por: Berger, Madeleine, et al.
Publicado: (2016)

Therapeutic Prospects of Exon Skipping for Epidermolysis Bullosa
por: Vermeer, Franciscus C., et al.
Publicado: (2021)

Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report
por: Chen, Zhuxing, et al.
Publicado: (2021)

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION
por: Bestvina, Christine M, et al.
Publicado: (2021)

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION
por: Leighl, Natasha, et al.
Publicado: (2022)

Prediction of alternatively skipped exons and splicing enhancers from exon junction arrays
por: Kechris, Katerina, et al.
Publicado: (2008)

Classifying Included and Excluded Exons in Exon Skipping Event Using Histone Modifications
por: Chen, Wei, et al.
Publicado: (2018)

A Genotype-Phenotype Correlation Study of Exon Skip-Equivalent In-Frame Deletions and Exon Skip-Amenable Out-of-Frame Deletions across the DMD Gene to Simulate the Effects of Exon-Skipping Therapies: A Meta-Analysis
por: Anwar, Saeed, et al.
Publicado: (2021)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
por: Digumarthy, Subba R., et al.
Publicado: (2019)

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
por: Fujino, Toshio, et al.
Publicado: (2021)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease
por: Blaquier, Juan Bautista, et al.
Publicado: (2022)

Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation
por: Nitta, Naohiro, et al.
Publicado: (2023)

Capmatinib‑associated interstitial lung disease in a patient with lung adenocarcinoma harboring a skipping mutation of mesenchymal‑epithelial transition exon 14: A case report
por: Lee, Bing-Jie, et al.
Publicado: (2023)

Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14 Skipping
por: Yang, Mo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g8ft6j43alelivu1qkijev9l97